_id
691093f4ccc777a4e85d5a6d
Ticker
EDAP
Name
EDAP TMS SA
Exchange
NASDAQ
Address
Parc dActivites la Poudrette-Lamartine, Vaulx-En-Velin, France, 69120
Country
USA
Sector
Healthcare
Industry
Medical Distribution
Currency
USD
Website
https://focalone.com
Description
EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The Distribution segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing and sales channels, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Vaulx-en-Velin, France.
Last Close
2.35
Volume
19437
Current Price
2.88
Change
22.553191489361694
Last Updated
2025-11-29T12:33:20.027Z
Image
data:image/webp;base64,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
Ipo Date
1997-07-31T00:00:00.000Z
Market Cap
89741016
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.11558333333333332
Sentiment Sources
12
Rating
3.3333
Target Price
5.8333
Strong Buy
0
Buy
1
Hold
2
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
13879000
Cost Of Revenue
7908000
Gross Profit
5971000
Operating Expenses
10897000
Operating Income
-4926000
Interest Expense
49000
Pretax Income
-4911000
Net Income
-5014000
Eps
-0.1339258407692803
Dividends Per Share
-
Shares Outstanding
37392086
Income Tax Expense
103000
EBITDA
-4220750
Operating Margin
-35.49247063909504
Total Other Income Expense Net
15000
Cash
10567000
Short Term Investments
-
Receivables
19025000
Inventories
13799000
Total Current Assets
44352000
Property Plant Equipment
10016000
Total Assets
61464000
Payables
16844000
Short Term Debt
5048000
Long Term Debt
1009000
Total Liabilities
38143000
Equity
23321000
Depreciation
641250
Change In Working Capital
-70974
Cash From Operations
-3279000
Capital Expenditures
908000
Cash From Investing
-908000
Cash From Financing
-1449000
Net Change In Cash
-16265000
PE
-
PB
4.623440435658848
ROE
-21.49993568028815
ROA
-8.157620721072497
FCF
-4187000
Fcf Percent
-0.3016787953022552
Piotroski FScore
1
Health Score
20
Deep Value Investing Score
2
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
1.5
Growth Investing Score
1
Momentum Investing Score
4.5
Net Net Investing Score
1
Quality Investing Score
1.5
Value Investing Score
2.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
13879000
Quarters > 0 > income Statement > cost Of Revenue
7908000
Quarters > 0 > income Statement > gross Profit
5971000
Quarters > 0 > income Statement > operating Expenses
10897000
Quarters > 0 > income Statement > operating Income
-4926000
Quarters > 0 > income Statement > interest Expense
49000
Quarters > 0 > income Statement > pretax Income
-4911000
Quarters > 0 > income Statement > net Income
-5014000
Quarters > 0 > income Statement > eps
-0.1339258407692803
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
37438630
Quarters > 0 > income Statement > income Tax Expense
103000
Quarters > 0 > income Statement > EBITDA
-4220750
Quarters > 0 > income Statement > operating Margin
-35.49247063909504
Quarters > 0 > income Statement > total Other Income Expense Net
15000
Quarters > 0 > balance Sheet > cash
10567000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
19025000
Quarters > 0 > balance Sheet > inventories
13799000
Quarters > 0 > balance Sheet > total Current Assets
44352000
Quarters > 0 > balance Sheet > property Plant Equipment
10016000
Quarters > 0 > balance Sheet > total Assets
61464000
Quarters > 0 > balance Sheet > payables
16844000
Quarters > 0 > balance Sheet > short Term Debt
5048000
Quarters > 0 > balance Sheet > long Term Debt
1009000
Quarters > 0 > balance Sheet > total Liabilities
38143000
Quarters > 0 > balance Sheet > equity
23321000
Quarters > 0 > cash Flow > net Income
-5014000
Quarters > 0 > cash Flow > depreciation
641250
Quarters > 0 > cash Flow > change In Working Capital
-70974
Quarters > 0 > cash Flow > cash From Operations
-3279000
Quarters > 0 > cash Flow > capital Expenditures
908000
Quarters > 0 > cash Flow > cash From Investing
-908000
Quarters > 0 > cash Flow > cash From Financing
-1449000
Quarters > 0 > cash Flow > net Change In Cash
-16265000
Quarters > 0 > ratios > PE
-0.1339258407692803
Quarters > 0 > ratios > PB
4.623440435658848
Quarters > 0 > ratios > ROE
-21.49993568028815
Quarters > 0 > ratios > ROA
-8.157620721072497
Quarters > 0 > ratios > FCF
-4187000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-0.3016787953022552
Quarters > 0 > health Score
20
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
16043000
Quarters > 1 > income Statement > cost Of Revenue
9221000
Quarters > 1 > income Statement > gross Profit
6822000
Quarters > 1 > income Statement > operating Expenses
12591000
Quarters > 1 > income Statement > operating Income
-5769000
Quarters > 1 > income Statement > interest Expense
57000
Quarters > 1 > income Statement > pretax Income
-5507000
Quarters > 1 > income Statement > net Income
-5600000
Quarters > 1 > income Statement > eps
-0.14976431108978513
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
37392086
Quarters > 1 > income Statement > income Tax Expense
93000
Quarters > 1 > income Statement > EBITDA
-5126750
Quarters > 1 > income Statement > operating Margin
-35.959608552016455
Quarters > 1 > income Statement > total Other Income Expense Net
262000
Quarters > 1 > balance Sheet > cash
16265000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
18527000
Quarters > 1 > balance Sheet > inventories
15531000
Quarters > 1 > balance Sheet > total Current Assets
51480000
Quarters > 1 > balance Sheet > property Plant Equipment
10202000
Quarters > 1 > balance Sheet > total Assets
68343000
Quarters > 1 > balance Sheet > payables
18549000
Quarters > 1 > balance Sheet > short Term Debt
6276000
Quarters > 1 > balance Sheet > long Term Debt
1022000
Quarters > 1 > balance Sheet > total Liabilities
40521000
Quarters > 1 > balance Sheet > equity
27822000
Quarters > 1 > cash Flow > net Income
-6352226
Quarters > 1 > cash Flow > depreciation
641250
Quarters > 1 > cash Flow > change In Working Capital
-91387
Quarters > 1 > cash Flow > cash From Operations
-4656625
Quarters > 1 > cash Flow > capital Expenditures
1598784
Quarters > 1 > cash Flow > cash From Investing
-1598788
Quarters > 1 > cash Flow > cash From Financing
60943
Quarters > 1 > cash Flow > net Change In Cash
16265000
Quarters > 1 > ratios > PE
-0.14976431108978513
Quarters > 1 > ratios > PB
3.8706494026310114
Quarters > 1 > ratios > ROE
-20.12795629358062
Quarters > 1 > ratios > ROA
-8.193962805261695
Quarters > 1 > ratios > FCF
-6255409
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-0.38991516549273825
Quarters > 1 > health Score
20
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
13558000
Quarters > 2 > income Statement > cost Of Revenue
7863000
Quarters > 2 > income Statement > gross Profit
5695000
Quarters > 2 > income Statement > operating Expenses
11691000
Quarters > 2 > income Statement > operating Income
-5996000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-6937000
Quarters > 2 > income Statement > net Income
-7074000
Quarters > 2 > income Statement > eps
-0.18918441725877502
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
37392086
Quarters > 2 > income Statement > income Tax Expense
137000
Quarters > 2 > income Statement > EBITDA
-5354750
Quarters > 2 > income Statement > operating Margin
-44.224811919162114
Quarters > 2 > income Statement > total Other Income Expense Net
-941000
Quarters > 2 > balance Sheet > cash
22825000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
16200000
Quarters > 2 > balance Sheet > inventories
18024000
Quarters > 2 > balance Sheet > total Current Assets
58470000
Quarters > 2 > balance Sheet > property Plant Equipment
9989000
Quarters > 2 > balance Sheet > total Assets
74976000
Quarters > 2 > balance Sheet > payables
17340000
Quarters > 2 > balance Sheet > short Term Debt
5687000
Quarters > 2 > balance Sheet > long Term Debt
1618000
Quarters > 2 > balance Sheet > total Liabilities
40518000
Quarters > 2 > balance Sheet > equity
34458000
Quarters > 2 > cash Flow > net Income
-7445124
Quarters > 2 > cash Flow > depreciation
641250
Quarters > 2 > cash Flow > change In Working Capital
866581
Quarters > 2 > cash Flow > cash From Operations
-5339363
Quarters > 2 > cash Flow > capital Expenditures
1303026
Quarters > 2 > cash Flow > cash From Investing
-1303027
Quarters > 2 > cash Flow > cash From Financing
-1252547
Quarters > 2 > cash Flow > net Change In Cash
-30895178
Quarters > 2 > ratios > PE
-0.18918441725877502
Quarters > 2 > ratios > PB
3.1252309385338672
Quarters > 2 > ratios > ROE
-20.52934006616751
Quarters > 2 > ratios > ROA
-9.435019206145967
Quarters > 2 > ratios > FCF
-6642389
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-0.48992395633574276
Quarters > 2 > health Score
20
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
20318000
Quarters > 3 > income Statement > cost Of Revenue
11221000
Quarters > 3 > income Statement > gross Profit
9097000
Quarters > 3 > income Statement > operating Expenses
12835000
Quarters > 3 > income Statement > operating Income
-3738000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-1952000
Quarters > 3 > income Statement > net Income
-1941000
Quarters > 3 > income Statement > eps
-0.052131173958585124
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
37233000
Quarters > 3 > income Statement > income Tax Expense
-11000
Quarters > 3 > income Statement > EBITDA
-3096750
Quarters > 3 > income Statement > operating Margin
-18.397480066935724
Quarters > 3 > income Statement > total Other Income Expense Net
1786000
Quarters > 3 > balance Sheet > cash
29836000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
20290000
Quarters > 3 > balance Sheet > inventories
18495000
Quarters > 3 > balance Sheet > total Current Assets
69876000
Quarters > 3 > balance Sheet > property Plant Equipment
10335000
Quarters > 3 > balance Sheet > total Assets
86063000
Quarters > 3 > balance Sheet > payables
12557000
Quarters > 3 > balance Sheet > short Term Debt
9819000
Quarters > 3 > balance Sheet > long Term Debt
2162000
Quarters > 3 > balance Sheet > total Liabilities
45167000
Quarters > 3 > balance Sheet > equity
40896000
Quarters > 3 > cash Flow > net Income
-2069383
Quarters > 3 > cash Flow > depreciation
641250
Quarters > 3 > cash Flow > change In Working Capital
299000
Quarters > 3 > cash Flow > cash From Operations
1211000
Quarters > 3 > cash Flow > capital Expenditures
1268000
Quarters > 3 > cash Flow > cash From Investing
-1287000
Quarters > 3 > cash Flow > cash From Financing
5454000
Quarters > 3 > cash Flow > net Change In Cash
30895178
Quarters > 3 > ratios > PE
-0.052131173958585124
Quarters > 3 > ratios > PB
2.6220422535211267
Quarters > 3 > ratios > ROE
-4.74618544600939
Quarters > 3 > ratios > ROA
-2.255324587801959
Quarters > 3 > ratios > FCF
-57000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
-0.00280539423171572
Quarters > 3 > health Score
26
Valuation > metrics > PE
-0.1339258407692803
Valuation > metrics > PB
4.623440435658848
Valuation > final Score
33.765595643411515
Valuation > verdict
54.1% Overvalued
Profitability > metrics > ROE
-21.49993568028815
Profitability > metrics > ROA
-11.305014430014431
Profitability > metrics > Net Margin
-0.3612652208372361
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
1.6355645126709832
Risk > metrics > Interest Coverage
-100.53061224489795
Risk > final Score
-372
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.0259455508861683
Liquidity > metrics > Quick Ratio
1.3956239722272976
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
41.29350597368989
Prev Valuations > 1
48.74769061466133
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-375
Prev Risks > 1
15
Prev Risks > 2
17
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:24:51.831Z
EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The Distribution segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing and sales channels, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Vaulx-en-Velin, France.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AEDAP TMS (NASDAQ:EDAP) Has Debt But No Earnings; Should You Worry? simplywall.st
Read more →European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week marketscreener.com
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
HOLD
Target Price:
$5.8333
Analyst Picks
Strong Buy
0
Buy
1
Hold
2
Sell
0
Strong Sell
0
Sentiment:
Neutral
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 38.96% of the total shares of EDAP TMS SA
1.
Soleus Capital Management, L.P.(19.5476%)
since
2025/06/30
2.
Morgan Stanley - Brokerage Accounts(8.9981%)
since
2025/06/30
3.
Rock Springs Capital Management LP(3.3964%)
since
2025/06/30
4.
Bruce & Co Inc(1.4807%)
since
2025/06/30
5.
Bruce(1.4169%)
since
2025/06/30
6.
Apis Capital Advisors, LLC(0.6052%)
since
2025/06/30
7.
UBS Group AG(0.4772%)
since
2025/06/30
8.
Schonfeld Strategic Advisors LLC(0.4604%)
since
2025/06/30
9.
Parkman Healthcare Partners LLC(0.4141%)
since
2025/06/30
10.
OHE Financial Inc(0.3609%)
since
2025/06/30
11.
Summit Trail Advisors, LLC(0.2737%)
since
2025/06/30
12.
Sage Mountain Advisors LLC(0.2674%)
since
2025/06/30
13.
PSM Growth UI(0.2139%)
since
2025/06/30
14.
Cetera Investment Advisers(0.2006%)
since
2025/06/30
15.
Commonwealth Equity Services Inc(0.185%)
since
2025/06/30
16.
Citadel Advisors Llc(0.1354%)
since
2025/06/30
17.
Orion Capital Management LLC(0.1016%)
since
2025/06/30
18.
Simplicity Wealth,LLC(0.087%)
since
2025/06/30
19.
BNP Paribas Arbitrage, SA(0.0698%)
since
2025/06/30
20.
INTREPID FAMILY OFFICE LLC(0.0669%)
since
2025/06/30
21.
Geode Capital Management, LLC(0.0609%)
since
2025/06/30
22.
Fidelity Nasdaq Composite Index(0.0609%)
since
2025/07/31
23.
Accredited Investors Inc(0.0573%)
since
2025/06/30
24.
LUX IM Global Medtech HX(0.0207%)
since
2025/08/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.